For many diabetes patients, their Actos prescription is a chance to manage a disease that dominates their lives. Pioglitazone treatments such as Actos, however, also impose a number of health risks, including the possibility that patients will develop bladder cancer if they take Actos beyond one year.
The Food and Drug Administration (FDA) has issued a warning to manufacturers, physicians, and patients about the side effects of Actos, but other health organizations have been even more aggressive steps. On the basis of a French study, for instance, France suspended the use of pioglitazone altogether and Germany recommended that doctors not prescribe pioglitazone to new patients. The response to Actos by the international health community raises important questions about whether the manufacturers of pioglitazone treatments have taken the appropriate steps to warn patients about the potentially lethal side effects of this dangerous drug.
———
About Nachawati Law Group
Nachawati Law Group represents parties in mass tort litigation, businesses and governmental entities in contingent litigation, and individuals in complex personal injury litigation. For more information, visit contact or call 214-890-0711.
